Odimma Therapeutics, a biotechnology company developing next-generation personalized cancer immunotherapies, today announced the submission of a first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for ODI-2001, its innovative multi-component therapeutic platform.
This first-in-human clinical trial will be conducted across several centres in France and will enrol patients with advanced digestive cancers. The study is investigator-initiated and sponsored by the Centre Georges-François Leclerc (CGFL) in Dijon, a leading comprehensive cancer centre.
Professor François Ghiringhelli, principal investigator of the study, commented:
“ODI-2001 represents a highly innovative approach to cancer vaccination, aiming to stimulate strong and durable anti-tumour immune responses. We are eager to bring this promising therapeutic strategy to patients with digestive tumours, where new treatment options are urgently needed.”
About ODI-2001
ODI-2001 is a personalized immunotherapy platform combining synthetic linear DNA encoding patient-specific neoantigens, a Modified Vaccinia Ankara (MVA) viral vector as an immunologic booster, and a low-dose immune checkpoint inhibitor to enhance T-cell priming. The therapy is designed to generate robust, targeted, and long-lasting immune responses against each patient’s tumour.
About Odimma Therapeutics
Odimma Therapeutics is a Strasbourg-based biotechnology company pioneering a new generation of personalized immunotherapies in oncology. Leveraging cutting-edge immune engineering, Odimma develops innovative therapeutic solutions with the potential to transform cancer treatment.